TransMedics Group (NASDAQ:TMDX) Rating Increased to Buy at Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

TMDX has been the subject of several other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $142.00 target price on shares of TransMedics Group in a report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a “hold” rating and a $115.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $127.18.

TransMedics Group Stock Up 1.7%

NASDAQ:TMDX opened at $117.63 on Friday. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $145.50. The stock has a market capitalization of $4.01 billion, a P/E ratio of 60.95 and a beta of 2.08. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The company’s 50-day simple moving average is $116.52 and its 200-day simple moving average is $113.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million for the quarter, compared to analysts’ expectations of $146.64 million. During the same period last year, the business earned $0.35 EPS. The company’s revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock valued at $209,448,000 after buying an additional 2,209,996 shares during the period. Geode Capital Management LLC raised its holdings in TransMedics Group by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock valued at $107,845,000 after buying an additional 11,241 shares during the period. Driehaus Capital Management LLC raised its holdings in TransMedics Group by 2.4% in the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company’s stock valued at $52,395,000 after buying an additional 17,913 shares during the period. Marshall Wace LLP increased its stake in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.